SCHEMBL333753

SCHEMBL333753

Cc1c(F)cccc1NC(=O)Nc1ccc(Cl)c(S(=O)(=O)N2[C@@H]3CC[C@H]2C/C(=N/O)C3)c1O

nearest known ligand 0.66

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 20/20 0.66
CX3CR1 P49238 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10077671 1.00 CXCR2 (0.66) CXCR2CX3CR1
SCHEMBL333754 1.00 CXCR2 (0.66) CXCR2CX3CR1
SCHEMBL333755 1.00 CXCR2 (0.66) CXCR2CX3CR1
SCHEMBL334117 0.90 CXCR2 (0.69) CXCR2CX3CR1
SCHEMBL10084131 0.88 CXCR2 (0.71) CXCR2CX3CR1
SCHEMBL334864 0.85 CXCR2 (0.69) CXCR2CX3CR1
SCHEMBL10077669 0.85 CXCR2 (0.69) CXCR2CX3CR1
SCHEMBL334358 0.83 CXCR2 (0.66) CXCR2CX3CR1
SCHEMBL10077644 0.83 CXCR2 (0.66) CXCR2CX3CR1
SCHEMBL335013 0.82 CXCR2 (0.63) CXCR2CX3CR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090298810-A1 IL-8 Receptor Antagonists SMITHKLINE BEECHAM CORPORATION 2009-12-03 US claimed
US-8097626-B2 IL-8 receptor antagonists GLAXOSMITHKLINE LLC (US) 2012-01-17 US disclosed
US-20090298810-A1 IL-8 Receptor Antagonists SMITHKLINE BEECHAM CORPORATION 2009-12-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090298810-A1 IL-8 Receptor Antagonists CXCL8, CCR8, IL1RN CXCR2 6/4885CX3CR1 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.